Your browser doesn't support javascript.
loading
LncRNA CBR3-AS1 is associated with the BCR::ABL1 kinase independent mechanism of tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia patients.
Lin, Wuqiang; Chen, Xiuli; Zheng, Heyong; Cai, Zhenjie; Xie, Linjun; Zhang, Beibei; Zheng, Rongrong.
Afiliação
  • Lin W; Department of Hematology, the First Hospital of Putian City, Putian, China.
  • Chen X; School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
  • Zheng H; Department of Hematology, the First Hospital of Putian City, Putian, China.
  • Cai Z; Department of Hematology, the First Hospital of Putian City, Putian, China.
  • Xie L; Department of Hematology, the First Hospital of Putian City, Putian, China.
  • Zhang B; Department of Hematology, the First Hospital of Putian City, Putian, China.
  • Zheng R; Department of Hematology, the First Hospital of Putian City, Putian, China.
Transl Cancer Res ; 13(7): 3262-3272, 2024 Jul 31.
Article em En | MEDLINE | ID: mdl-39145066
ABSTRACT

Background:

It is difficult for chronic myeloid leukemia (CML) patients with BCRABL1 independent drug resistance to achieve optimal efficacy. The aim of this study is to investigate the BCRABL1 kinase independent mechanism of tyrosine kinase inhibitor (TKI) resistance in CML patients to develop targeted therapeutic strategy.

Methods:

Herein, we analyzed the long non-coding RNA (lncRNA) and messenger RNA (mRNA) expression profiles of patients who achieved sustained deep molecular response (DMR) after TKI treatment and patients with non-DMR using RNA-seqencing. Furthermore, the differentially expressed lncRNAs and mRNAs were identified. The expression of chosen lncRNA was validated in an expanded cohort, and bioinformatics analysis was performed to analyze the function of selected mRNA.

Results:

LncRNA data analysis indicated the diversity lncRNA profiles among healthy individuals, CML patients with non-DMR, and CML patients with DMR. Differential expression analysis and Veen plot of up-regulated lncRNAs in patients with non-DMR (compared with healthy individuals) and down-regulated lncRNAs in patients with DMR (compared to patients with non-DMR) revealed that lncRNA CBR3-AS1 overexpression might be related to BCRABL1 independent TKI resistance of CML patients. The expression of CBR3-AS1 was then verified in an expanded cohort, suggesting that, compared with control group, there was no statistical difference of CBR3-AS1 expression in DMR group, whereas, CBR3-AS1 was up-regulated in non-DMR group. Moreover, the mRNA data analysis of RNA-sequencing was performed. We considered genes that up-regulated in non-DMR group (compared with control group), down-regulated in DMR group (compared with non-DMR group), showed no statistical difference between control and DMR group as the potential genes that associated with TKI resistance of CML patients. A total of 55 corresponding mRNAs were obtained including KCNA6, a target gene of CBR3-AS1. Further bioinformatics analysis showed that the major interacted genes of KCNA6 were enriched in several resistance-associated pathways including interleukin -17 signaling pathway and cyclic adenosine monophosphate signaling pathway.

Conclusions:

In conclusion, this work indicates that CBR3-AS1 might be involved in BCRABL1 independent TKI resistance of CML patients through targeting KCNA6, providing a novel target for intervention treatment of CML patients with BCRABL1 independent TKI resistance.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Transl Cancer Res Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Transl Cancer Res Ano de publicação: 2024 Tipo de documento: Article